We are international
Donate
• videos TEXT SIZE   

INTERNATIONAL MYELOMA WORKSHOP 2011

May 3-6, 2011, Paris played host to over 2000 myeloma specialists from all over the world. It was the 13th International Myeloma Workshop, held every two years to highlight emerging advances in our understanding of the biology and treatment of myeloma. The IMF was there to film it. Why not start with the Session Summaries?

Session Summaries
Opening Remarks
Molecular Pathways/Genetics
Plasma Cell Biology
Bone Disease and Animal Models
Newly Diagnosed <65 Years
High-Risk Entities of Myeloma
Debate: Should We Treat Stage I MM?
Management of Myeloma Bone Disease
MM Cast Nephropathy & AL Amyloidosis
Newly Diagnosed >65 Years
New Drugs and Therapeutic Approaches
Secondary Malignancy in Myeloma
Plenary Abstract Session I
Monoclonal Immunoglobulin and the Nerve, Waldenstrom's Macroglobulinemia
Plenary Abstract Session II
Consensus Report
Novel Agents Updates
International Myeloma Workshop 2011
Dr. Fonseca - MOLECULAR PATHWAYS/GENETICS SESSION SUMMARY
Rafael Fonseca,MD
Mayo Clinic Arizona
May 3-6, 2011
Paris, France
International Myeloma Workshop 2011
Dr. Klein - PLASMA CELL BIOLOGY SESSION SUMMARY
Dr. Bernard Klein
Institute of Research in Biotherapy, Montpellier, France
May 3-6, 2011
Paris, France

International Myeloma Workshop 2011
Dr. Giuliani - BONE DISEASE AND ANIMAL MODELS SESSION SUMMARY
Nicola Giuliani, MD
University of Parma, Parma, Italy
May 3-6, 2011
Paris, France
International Myeloma Workshop 2011
Dr. Boccadoro - NEWLY DIAGNOSED MYELOMA <65 YEARS: FACTS & QUESTIONS SESSION SUMMARY
Mario Boccadoro, MD
Università di Torino, Torino, Italy
May 3-6, 2011
Paris, France

International Myeloma Workshop 2011
Dr. Morgan - HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT SESSION SUMMARY
Gareth Morgan, MD
Royal Marsden Hospital, Sutton, United Kingdom
May 3-6, 2011
Paris, France
International Myeloma Workshop 2011
Dr. Stewart - HIGH-RISK ENTITIES OF MYELOMA: FROM BIOLOGY TO TREATMENT SESSION SUMMARY
Dr. A. Keith Stewart
Mayo Clinic Arizona, Scottsdale, Arizona, USA
May 3-6, 2011
Paris, France

International Myeloma Workshop 2011
Dr.Lonial - DEBATE: SHOULD WE TREAT SOME PATIENTS WITH STAGE I MM? SESSION SUMMARY
Sagar Lonial, MD
Emory University School of Medicine, Atlanta, Georgia, USA
May 3-6, 2011
Paris, France
International Myeloma Workshop 2011
Dr. Raje - PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE SESSION SUMMARY
Noopur Raje, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, USA
May 3-6, 2011
Paris, France

International Myeloma Workshop 2011
Dr. Terpos - PRACTICAL ASPECTS ON THE MANAGEMENT OF MYELOMA BONE DISEASE SESSION SUMMARY
Evangelos Terpos, MD
University of Athens School of Medicine, Athens, Greece
May 3-6, 2011
Paris, France
International Myeloma Workshop 2011
Dr. Merlini - MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSIS SESSION SUMMARY
GiamPaolo Merlini, MD
Policlinico San Matteo, Pavia, Italy
May 3-6, 2011
Paris, France

International Myeloma Workshop 2011
Dr. Mateos - NEWLY DIAGNOSED MYELOMA >65 YEARS: FACTS & QUESTIONS SESSION SUMMARY
María Victoria Mateos, MD
University Hospital of Salamanca, Salamanca, Spain
May 3-6, 2011
Paris, France
International Myeloma Workshop 2011
Dr.Palumbo - NEWLY DIAGNOSED MYELOMA>65 YEARS: FACTS & QUESTIONS SESSION SUMMARY
Antonio Palumbo, MD
Ospedale Molinette, Torino, Italy
May 3-6, 2011
Paris, France

International Myeloma Workshop 2011
Dr.Rajkumar - NEWLY DIAGNOSED MYELOMA >65 YEARS: FACTS & QUESTIONS SESSION SUMMARY
S. Vincent Rajkumar, MD
Mayo CLinic, Rochester, Minnesota, USA
May 3-6, 2011
Paris, France
International Myeloma Workshop 2011
Dr.Jagannath - NEW DRUGS AND THERAPEUTIC APPROACHES SESSION SUMMARY
Sundar Jagannath, MD
Mt. Sinai Cancer Institute, New York, New York, USA
May 3-6, 2011
Paris, France

International Myeloma Workshop 2011
Dr.Landgren - SECONDARY MALIGNANCY IN MYELOMA: AN EMERGING ISSUE? SESSION SUMMARY
Ola Landgren, MD
National Cancer Institute, Bethesda, Maryland, USA
May 3-6, 2011
Paris, France